Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2023-03-28 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Pursuant to the Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find attached herewith ....
Regulatory Filings
2023-03-28 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement informing the stock exchanges about the successful completion of a USFDA inspection of the company's API manufacturing facility without any adverse observations. It is dated and addressed to the National Stock Exchange of India and BSE Limited, indicating a regulatory disclosure. The content does not contain any financial data, detailed report, or management discussion. It is a compliance and regulatory update rather than a financial report or detailed filing. Given the short length (1579 characters) and the nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-03-25 English
This is to inform you that the United States Food and Drug Administration ('USFDA') conducted an inspection of the API manufacturing facility, at Baddi, Himachal Pradesh, of the company. The ....
Regulatory Filings Classification · 95% confidence The document is a short announcement informing the stock exchanges about the successful completion of a USFDA inspection of the company's API manufacturing facility without any adverse observations. It is dated and addressed to the National Stock Exchange of India and BSE Limited, indicating a regulatory or compliance update. The document does not contain any financial data, detailed report, or presentation materials. It is a brief notification rather than a full report or detailed filing. Given its nature and length (1579 characters), it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-03-25 English
Loss of Share Certificates
Regulatory Filings
2023-03-20 English
Loss of Share Certificates
Regulatory Filings
2023-03-20 English
Pursuant to the Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find attached herewith ....
Regulatory Filings
2023-03-20 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.